E
EQRx
Biotech & Life Sciences · Cambridge, United States · Founded 2019 · Public via SPAC 2021
Biotech company aimed at creating less expensive medicine MoreLess
EQRx is a biotechnology company focused on developing and delivering innovative medicines at significantly lower prices. The company aims to address the high cost burden of healthcare by creating a catalog of new medicines that are more affordable and accessible. EQRx operates in the pharmaceutical and healthcare markets, targeting disease areas with the highest cost burdens on society. The business model revolves around leveraging cutting-edge innovation and strategic collaborations to produce high-quality, cost-effective treatments. EQRx generates revenue by bringing these affordable medicines to market, thereby increasing access to essential healthcare solutions for a broader population. The company's clients include healthcare providers, patients, and payers who benefit from reduced costs and improved access to new treatments. EQRx's mission is to transform the healthcare system by making it more sustainable and equitable through innovative and affordable medical solutions.
Keywords: biotechnology, affordable medicines, healthcare innovation, pharmaceutical, cost-effective treatments, strategic collaborations, disease burden, healthcare providers, patients, payers.
Talent graph
EQRx's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where EQRx has talent and traffic
across markets
Market sentiment
What the market is saying about EQRx
An AI-synthesized read of the highest-engagement posts about EQRx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EQRx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

















